Genitourinary and STI Pathogens

Rapid Detection of Genitourinary and STI Pathogens

HealthTrackRx (HTRx) is the premier specialty diagnostic laboratory dedicated to the detection of infectious diseases.

With a decades-long track record of industry-leading technological advancement, our assays deliver accurate, actionable data with best-in-class turnaround time.

99% of samples received by our lab are reported out within 24-36 hours of receipt.

Eliminate the Guesswork in Diagnosis and Treatment

Our Genito-STI pathogen assay utilizes the latest in quantitative RT-PCR technology to rapidly and reliably analyze your patient’s sample.

We rapidly detect and differentiate 99% of the most relevant relevant bacterial, viral, and fungal pathogens including:

  • One of the most complete selections of High Risk HPV (human papilloma virus) types
  • Robust coverage of agents causative of Pelvic Inflammatory Disease (PID), endometritis, cervical vaginitis (bacterial vaginosis), vulvitis, urethritis, prostatitis, cystitis, and Genito-urinary ulcers

Our molecular technique provides a more definitive diagnosis than POC antigen assays and conventional culture.

Our Genito-STI Diagnostics:

  • Reduce false negatives
  • Detect polymicrobial infections
  • Are unaffected by concurrent antibiotic use
  • Include one of the most extensive antibiotic resistance gene menus
  • Reduce unnecessary drug exposure and adverse events
  • Report within 24-36 hours of sample receipt

Prescribe with Confidence

As the leader in testing sensitivity and specificity, our reports include a custom-designed accurate and detailed antibiogram.

  • Support antibiotic stewardship by reducing over-utilization of broad-spectrum anti-infectives
  • Decrease the need for empiric therapy
  • Reduce unnecessary drug exposure, adverse events, cost of repeat testing, and multiple treatment attempts

The New 99%

  • Over 99% of results are reported within 24-36 hours of sample receipt

  • Over 99% sensitivity to reduce false negatives

  • Over 99% specificity to reduce false positives

  • Over 99% of the most common pathogens detected

  • 100% trackable samples and results

Genito-STD Pathogens

  • Acinetobacter baumanii

  • Actinomyces israelii

  • Atopobium vaginae

  • Bacteroides fragilis

  • BVAB 2,3 (bacterial vaginosis associated bacteria 1-3); Mobiluncus spp

  • Candida albicans, glabrata, parapsilosis, tropicalis

  • Candida auris

  • Chlamydia trachomatis

  • Citrobacter freundii

  • Cytomegalovirus (CMV, Human Herpesvirus-5)

  • Escherichia coli

  • Enterobacter aerogenes, cloacae

  • Enterococcus faecalis, faecium

  • Gardnerella vaginalis

  • Haemophilus ducreyi

  • Herpes simplex virus 1 & 2 (HSV-1, HSV-2)

  • High Risk HPV Types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 73, 82

  • Klebsiella (Calymmatobacterium) granulomatis

  • Klebsiella pneumoniae, oxytoca

  • Megasphaera (types 1, 2)

  • Morganella morganii

  • Mycoplasma genitalium, hominis

  • Neisseria gonorrhoeae

  • Peptostreptococcus anaerobius, asaccharolyticus, magnus, prevotii

  • Proteus mirabilis, vulgaris

  • Pseudomonas aeruginosa

  • Serratia marcescens

  • Staphylococcus (coagulase negative: epidermidis, haemolyticus, lugdunensis, saprophyticus)

  • Staphylococcus aureus

  • Streptococcus agalactiae (Group B strep (GBS))

  • Streptococcus pyogenes (Group A strep)

  • Treponema pallidum

  • Trichomonas vaginalis

  • Ureaplasma urealyticum, parvum

Antibiotic Resistance

  • VanA, VanB (Vancomycin resistance)
  • ermB, C; mefA (Macrolide Lincosamide Streptogramin)
  • SHV, KPC Groups (Class A beta lactamase)
  • dfr (A1, A5), sul (1, 2) probes (Trimethoprim/Sulfamethoxazole resistance)
  • mecA (Methicillin gene)
  • qnrA1, qnrA2, qnrB2 (Fluoroquinolone genes)
  • tet B, tet M (Tetracycline genes)
  • IMP, NDM, VIM Groups (Class B metallo beta lactamase)
  • ACT, MIR, FOX, ACC Groups (AmpC beta lactamase)
  • OXA-48,-51 (Class D oxacillinase)
  • CTX-M1 (15), M2 (2), M9 (9), M8/25 Groups (Class A beta lactamase)

Effective 7/13/2020

Learn More

Ready to improve outcomes with fast, accurate diagnostic results? Contact us to learn more.

Click below to schedule your consultation.

Schedule A Consultation